Intergrated Analysis of the Prognostic and Immunological Role of an Oncogenic Protein Four Jointed Box 1(FJX1)

Abstract

Abstract Background Four jointed box 1(FJX1) has been reported to be up-regulated in many cancers, and has indicated the important role in oncology and immunity. In order to further explore the biological function of FJX1 and find a new immunotherapy targets for cancers, we performed a pan-cancer analysis of FJX1. Methods We used Genotype-Tissue Expression(GTEx), The Cancer Genome Atlas(TCGA), cBioPorta, Immune Cell Abundance Identifier(ImmuCellAI), The Tumor Immune Estimation Resource version2(TIMER2), IMvigor210CoreBiologies and Genomics For Drug Sensitivity In Cancer(GDSC) to explored the potential carcinogenesis and immunological role of FJX1. The FJX1 expression profiles, prognostic value, mutation status, immune cell infiltration, immune-related genes, immunosuppressive pathway-related genes, immunotherapy effect and the IC50 related to FJX1 were analyzed. Cell proliferation assay, transwell migration assay and wound healing assay were conducted in colon cancer cells. Results The results demonstrated that FJX1 was highly expressed in most cancers and was significantly associated with poor prognosis. FJX1 expression were significantly correlated with CNA, DNA methylation, TMB and MSI in various cancers. Tumor associated macrophages (TAMs) was positively correlated with FJX1 in several tumors. Immune-related genes including TGFB1, IL-10, and immunosuppressive pathway-related genes including TGFB1 and WNT1 were positively related to FJX1 expression in most cancers. Moreover, High FJX1 expression could also reduce the efficacy of immunotherapy and contribute to drug resistance. Knocking down FJX1 could inhibit proliferation and migration in colon cancer cells. Conclusion Our study confirmed that FJX1 is an oncogene, a potential novel prognostic biomarker and a new immunotherapy target in pan-cancer.